Overview

Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-12-20

Target enrollment:

Participant gender:

Summary

This study is a single-arm, prospective, open-label clinical study to evaluate the safety and efficacy of tislelizumab combined with chemoradiotherapy in first-line treatment of patients with stage IVb esophageal squamous cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Xinxiang Medical College

Collaborator:

BeiGene